Literature DB >> 9610566

Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects.

P A di Sant'Agnese1.   

Abstract

Neuroendocrine cells of the prostate are intraepithelial regulatory cells that secrete serotonin and a variety of peptide hormones. It is hypothesized that these cells regulate both growth and differentiation, as well as exocrine secretory activity through endocrine, paracrine, neurocrine, and lumenocrine mechanisms. Neuroendocrine differentiation in prostatic carcinoma occurs as pure neuroendocrine malignancies, such as small-cell carcinoma and carcinoid/carcinoid-like tumors, as well as focal neuroendocrine differentiation in a more conventional prostatic adenocarcinoma. Neuroendocrine differentiation in prostatic carcinoma may have diagnostic and prognostic significance.

Entities:  

Mesh:

Year:  1998        PMID: 9610566     DOI: 10.1016/s0090-4295(98)00064-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

1.  Voltage-dependent ion channel currents in putative neuroendocrine cells dissociated from the ventral prostate of rat.

Authors:  Jun Hee Kim; Sun Young Shin; Sang Soon Yun; Tae Jin Kim; Seung-June Oh; Kwang Myung Kim; Young-Shin Chung; Eun-Kyoung Hong; Dae-Yong Uhm; Sung Joon Kim
Journal:  Pflugers Arch       Date:  2003-02-21       Impact factor: 3.657

2.  Biogenic amines serotonin and dopamine regulate cholangiocyte hyperplastic and neoplastic growth.

Authors:  Gabriel A Frampton; Huang Li; Jonathan Ramirez; Akimuddin Mohamad; Sharon Demorrow
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

Review 3.  MicroRNAs in prostate cancer: From function to biomarker discovery.

Authors:  Ahmed A Moustafa; Hogyoung Kim; Rasha S Albeltagy; Ola H El-Habit; Asim B Abdel-Mageed
Journal:  Exp Biol Med (Maywood)       Date:  2018-06

4.  SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.

Authors:  Xiaotun Zhang; Ilsa M Coleman; Lisha G Brown; Lawrence D True; Lori Kollath; Jared M Lucas; Hung-Ming Lam; Ruth Dumpit; Eva Corey; Lisly Chéry; Bryce Lakely; Celestia S Higano; Bruce Montgomery; Martine Roudier; Paul H Lange; Peter S Nelson; Robert L Vessella; Colm Morrissey
Journal:  Clin Cancer Res       Date:  2015-06-12       Impact factor: 12.531

5.  Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile.

Authors:  Alvin Y Liu; Martine P Roudier; Lawrence D True
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

6.  A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging.

Authors:  Yongjun Yan; Kai Chen; Min Yang; Xilin Sun; Shuanglong Liu; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-10-10       Impact factor: 3.520

7.  Invasive neuroendocrine tumor of the kidney: a case report.

Authors:  Ephrem O Olweny; Michael H Hsieh; Jill C Buckley; Jack W McAninch
Journal:  Rare Tumors       Date:  2009-12-28

8.  Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth.

Authors:  Gianfranco Alpini; Pietro Invernizzi; Eugenio Gaudio; Julie Venter; Shelley Kopriva; Francesca Bernuzzi; Paolo Onori; Antonio Franchitto; Monique Coufal; Gabriel Frampton; Domenico Alvaro; Sum P Lee; Marco Marzioni; Antonio Benedetti; Sharon DeMorrow
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

9.  Primary carcinoid tumor arising within mature teratoma of the kidney: report of a rare entity and review of the literature.

Authors:  Henry B Armah; Anil V Parwani
Journal:  Diagn Pathol       Date:  2007-05-17       Impact factor: 2.644

10.  Synchronous primary carcinoid tumor and primary adenocarcinoma arising within mature cystic teratoma of horseshoe kidney: a unique case report and review of the literature.

Authors:  Henry B Armah; Anil V Parwani; Aleksandr M Perepletchikov
Journal:  Diagn Pathol       Date:  2009-06-14       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.